REMAP-CAP / ATTACC / ACTIV-4a
2021
Therapeutic-Dose Heparin in COVID-19
In hospitalised COVID-19 patients across three coordinated platforms, therapeutic-dose heparin improved organ-support-free days in moderate illness but not in critically ill patients.
Result
Primary endpoint: Organ-support-free days at 21 days
Moderate-illness benefit; critically ill futility, possible harm.
- Subtopic
- Anticoagulation
- Design
- Coordinated multi-platform RCT
- Enrolled
- 3,398 patients
- Relevance
- Important: one of several pillars.
- Source
- ATTACC, ACTIV-4a, REMAP-CAP Investigators. N Engl J Med. 2021;385(9):790-802 and 385(9):777-789.doi 10.1056/NEJMoa2105911
Discussion & critique
Defined the moderate-vs-severe split for therapeutic anticoagulation in COVID-19.